Search Within

Hematologic Malignancies Research

Formats
  1. Journal Article (1545)
  2. Meeting Abstract (1260)
  3. Review (76)
  4. Editorial (35)
  5. Book Section (32)
  6. Research Letter (26)
  7. Conference Paper (15)
  8. Correspondence (8)
  9. Guidelines (4)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3005)
  2. GSK Faculty (2450)
  3. Department of Medicine (2318)
  4. Hematologic Malignancies, Division of (2120)
  5. Sloan Kettering Institute Faculty (2052)
  6. Molecular Pharmacology and Chemistry Program Faculty (1632)

More Groups

People
  1. Michel Sadelain (586)
  2. David Scheinberg (502)
  3. Alexander Lesokhin (381)
  4. Carl Landgren (336)
  5. Renier Brentjens (286)
  6. Gabriela Chiosis (281)

More People

Years
  1. 2025 (64)
  2. 2024 (131)
  3. 2023 (175)
  4. 2022 (126)
  5. 2021 (154)
  6. 2020 (173)

More Years

Publications
  1. Blood (660)
  2. Cancer Research (117)
  3. Journal of Clinical Oncology (112)
  4. Clinical Lymphoma, Myeloma and Leukemia (84)
  5. Biology of Blood and Marrow Transplantation (80)
  6. Molecular Therapy (68)

More Publications

Publishers
  1. American Society of Hematology (700)
  2. Nature Publishing Group (375)
  3. Elsevier Inc. (291)
  4. American Association for Cancer Research (245)
  5. American Society of Clinical Oncology (116)
  6. Cell Press (116)

More Publishers

Results (3005)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical factors associated with cytokine release syndrome and dosing recommendations for restarting elranatamab following an interruption
    Meeting Abstract

    Niesvizky, R.; Arnulf, B.; Mohty, M.; Nooka, A. K.; Manier, S.; Tomasson, M.; Bahlis, N. J.; Irby, D.; Hibma, J.; Viqueira, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Manufacturing, characterization and anti-tumor activity of allogeneic CD19-CAR cytokine-induced killer (CIK) cells engineered with non-viral sleeping beauty transposon system and armored with IL-18
    Meeting Abstract

    Contreras-Ruiz, L.; Pace, B.; Kohnke, D. E.; Viruet, L.; Adams, M.; Krisko, J. F.; Leesnitzer, N.; Velie, M.; Tettamanti, S.; Pisani, I.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in Black patients with relapsed/refractory multiple myeloma (RRMM): A Subgroup analysis of the magnetismm studies
    Meeting Abstract

    Varshavsky-Yanovsky, A.; Jethava, Y.; Stevens, D. A.; Nooka, A. K.; Stiff, P. J.; Perez-Cruz, I.; Leip, E.; Lesokhin, A.
    Blood (2023)

    Fulltext@MSK | Save
  • Whole-genome sequencing reveals distinct mutational signatures in multiple myeloma patients with African ancestry compared with those of non-African ancestry
    Meeting Abstract

    Maclachlan, K. H.; Blaney, P.; Cirrincione, A.; Chu, T. R.; Poos, A. M.; Brown, E. E.; Manasanch, E. E.; Hoering, A.; Hou, L. M.; Gagler, D.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Potent and target specific cytotoxicity of PRAME TCR mimic CAR T cells in KMT2A-rearranged AML patient-derived xenograft model
    Meeting Abstract

    Kirkey, D. C.; Robinson, L.; Hylkema, T.; Loeb, A.; Ries, R. E.; McKay, C.; Root, C.; Pardo, L.; Loeb, K. R.; Le, Q.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Dietary patterns among individuals with plasma cell disorders compared to the general US population
    Meeting Abstract

    Traore, K.; Taneja, A.; Gorshein, E.; Castro, F.; Derkach, A.; Martinez, J. A. H.; Serrano, E.; Lesokhin, A.; Ahlstrom, J. M.; Block, T.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • GLUT1 overexpression enhances 19-28z CAR-T cell expansion and metabolic fitness
    Meeting Abstract

    Shi, Y.; Kotchetkov, I. S.; Hanina, S. A.; Sadelain, M.
    Blood (2023)

    Fulltext@MSK | Save
  • Long term follow-up after treatment with allogeneic off-the-shelf CAR T cell therapy for relapsed or refractory B-cell malignancies
    Meeting Abstract

    Shahid, S.; Flynn, G. C.; Mauguen, A.; Bieler, J.; Prockop, S. E.; Scaradavou, A.; Boelens, J. J.; Sauter, C. S.; Perales, M. A.; Giralt, S. A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A phase 1b multi-center study of the FLT3 inhibitor gilteritinib in combination with the IDH1 inhibitor ivosidenib or the IDH2 inhibitor enasidenib for patients with relapsed or refractory acute myeloid leukemia who have co-occurring FLT3/IDH1 or FLT3/IDH2 mutations
    Meeting Abstract

    Stein, E. M.; Derkach, A.; Melamed, G.; Block, A.; Kim, J.; Georgieva, G.; Thompson, V.; Levine, R. L.; Intlekofer, A. M.; Abdel-Wahab, O.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Responses and outcomes after second-line therapy in transplant-eligible patients with DLBCL relapse over 1 year after first-line therapy
    Meeting Abstract

    Qualls, D. A.; Shah, G. L.; Shouval, R.; Caron, P.; David, K. A.; Falchi, L.; Ghione, P.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; more...
    Blood (2023)

    Fulltext@MSK | Save